Insider Transactions in Q1 2021 at Fate Therapeutics Inc (FATE)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2021
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
25,000
-4.5%
|
$2,300,000
$92.76 P/Share
|
|
Mar 15
2021
|
Bahram Valamehr Chief R&D Officer |
SELL
Exercise of conversion of derivative security
|
Direct |
25,000
-17.15%
|
$50,000
$2.9 P/Share
|
|
Mar 08
2021
|
Daniel D Shoemaker Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,000
-3.61%
|
$2,050,000
$82.55 P/Share
|
|
Feb 18
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
20,000
-0.98%
|
$2,020,000
$101.28 P/Share
|
|
Feb 18
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+4.61%
|
$120,000
$6.62 P/Share
|
|
Jan 22
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-1.82%
|
$2,940,000
$98.76 P/Share
|
|
Jan 22
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+3.46%
|
$120,000
$4.68 P/Share
|
|
Jan 21
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-0.91%
|
$3,090,000
$103.59 P/Share
|
|
Jan 21
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.61%
|
$60,000
$2.73 P/Share
|
|
Jan 20
2021
|
Edward J Dulac Iii Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,013
+23.69%
|
-
|
|
Jan 20
2021
|
Daniel D Shoemaker Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,411
+12.82%
|
-
|
|
Jan 20
2021
|
Cindy Tahl General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
18,013
+14.29%
|
-
|
|
Jan 20
2021
|
Bahram Valamehr Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,013
+15.84%
|
-
|
|
Jan 20
2021
|
J Scott Wolchko President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
43,231
+9.89%
|
-
|
|
Jan 19
2021
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
35,000
-7.71%
|
$4,025,000
$115.56 P/Share
|
|
Jan 19
2021
|
Cindy Tahl General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+21.87%
|
$70,000
$2.9 P/Share
|
|
Jan 11
2021
|
Daniel D Shoemaker Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,253
-1.26%
|
$357,830
$110.68 P/Share
|
|
Jan 11
2021
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
3,254
-1.18%
|
$357,940
$110.68 P/Share
|
|
Jan 11
2021
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
3,254
-1.36%
|
$357,940
$110.68 P/Share
|
|
Jan 11
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
8,587
-0.8%
|
$944,570
$110.68 P/Share
|
|
Jan 08
2021
|
Daniel D Shoemaker Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,229
-1.71%
|
$722,564
$116.33 P/Share
|
|
Jan 08
2021
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
6,229
-1.6%
|
$722,564
$116.33 P/Share
|
|
Jan 08
2021
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
6,230
-1.83%
|
$722,680
$116.33 P/Share
|
|
Jan 08
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
60,820
-3.8%
|
$7,055,120
$116.33 P/Share
|
|
Jan 08
2021
|
Redmile Group, LLC Director |
BUY
Open market or private purchase
|
Indirect |
327,485
+2.47%
|
$27,836,225
$85.5 P/Share
|